Tolerability of first-line therapy for metastatic renal cell carcinoma.

  title={Tolerability of first-line therapy for metastatic renal cell carcinoma.},
  author={Camillo Porta and Cezary A. Szczylik},
  journal={Cancer treatment reviews},
  volume={35 3},
The treatment options for metastatic renal cell carcinoma have expanded rapidly over the past 3 years, with four new agents available and others in late-stage development. This has resulted in a change of the standard of first-line care, with sunitinib or bevacizumab plus interferon the treatments of choice for patients with good or intermediate-risk renal cell carcinoma and temsirolimus treatment of choice for poor-risk disease. Sunitinib and bevacizumab plus interferon have similar efficacy… CONTINUE READING